Evidence map›Paper›PMID 31853661›Full record

ArticleJournal of cancer research and clinical oncology2020

Efficacy and safety of first-line pembrolizumab monotherapy in elderly patients (aged ≥ 75 years) with non-small cell lung cancer.

Hisao Imai, Satoshi Wasamoto, Ou Yamaguchi, Kensuke Suzuki, Tomohide Sugiyama, Junji Uchino, Hiroyuki Minemura, Takashi Osaki, Hisashi Ishii, Yukihiro Umeda and 8 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cancer research and clinical oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 3 pooled it
2.0field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 3 syntheses or guidelines pooled it, 30 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 10 institutions in 1 country.

Hisao ImaiDivision of Respiratory Medicine, Gunma Prefectural Cancer Center, 617-1, Takahayashinishi, Ota, Gunma, 373-8550, Japan. m06701014@gunma-u.ac.jp.ORCID http://orcid.org/0000-0003-3097-4255
Satoshi WasamotoDivision of Respiratory Medicine, Saku Central Hospital Advanced Care Center, Saku, Nagano, Japan.
Ou YamaguchiDepartment of Respiratory Medicine, Comprehensive Cancer Center, International Medical Center, Saitama University Hospital, Hidaka, Saitama, Japan.
Kensuke SuzukiDivision of Internal Medicine, Toyama Prefectural Central Hospital, Toyama, Toyama, Japan.
Tomohide SugiyamaDivision of Thoracic Oncology, Tochigi Cancer Center, Utsunomiya, Tochigi, Japan.
Junji UchinoDepartment of Pulmonary Medicine, Kyoto Prefectural University of Medicine, Kyoto, Kyoto, Japan.
Hiroyuki MinemuraDepartment of Pulmonary Medicine, Fukushima Medical University, Fukushima, Japan.
Takashi OsakiDivision of Respirology, National Hospital Organization Shibukawa Medical Center Hospital, Shibukawa, Gunma, Japan.
Hisashi IshiiDepartment of Pulmonary Medicine, Nishisaitama-Chuo National Hospital, Tokorozawa, Saitama, Japan.
Yukihiro UmedaThird Department of Internal Medicine, Faculty of Medical Sciences, University of Fukui, Eiheiji, Fukui, Japan.
Keita MoriClinical Research Promotion Unit, Clinical Research Center, Shizuoka Cancer Center, Nagaizumi, Shizuoka, Japan.
Mie KotakeDivision of Respiratory Medicine, Gunma Prefectural Cancer Center, 617-1, Takahayashinishi, Ota, Gunma, 373-8550, Japan.
Hiroshi KagamuDepartment of Respiratory Medicine, Comprehensive Cancer Center, International Medical Center, Saitama University Hospital, Hidaka, Saitama, Japan.
Nobutoshi MorozumiDivision of Respiratory Medicine, Saku Central Hospital Advanced Care Center, Saku, Nagano, Japan.
Hirokazu TaniguchiDivision of Internal Medicine, Toyama Prefectural Central Hospital, Toyama, Toyama, Japan.
Takashi KasaiDivision of Thoracic Oncology, Tochigi Cancer Center, Utsunomiya, Tochigi, Japan.
Koichi MinatoDivision of Respiratory Medicine, Gunma Prefectural Cancer Center, 617-1, Takahayashinishi, Ota, Gunma, 373-8550, Japan.
Kyoichi KairaDepartment of Respiratory Medicine, Comprehensive Cancer Center, International Medical Center, Saitama University Hospital, Hidaka, Saitama, Japan.
Saitama University · JPSaku Central Hospital · JPTochigi Cancer Center · JPToyama Prefectural Central Hospital · JPFukushima Medical University · JPGunma Children's Medical Center · JPKyoto Prefectural University of Medicine · JPNational Hospital Organization · JPShizuoka Cancer Center · JPUniversity of Fukui · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposePembrolizumab is an effective front-line treatment for advanced non-small cell lung cancer (NSCLC) in patients expressing high levels of programmed death-ligand 1 (PD-L1). However, it is unclear whether first-line pembrolizumab has similar efficacy among elderly (aged ≥ 75 years) and younger patients. This study aimed to investigate the safety and efficacy of front-line pembrolizumab monotherapy in older adults with NSCLC expressing high PD-L1.

methodsA total of 128 patients with advanced NSCLC expressing high PD-L1, including 47 older adults, received first-line pembrolizumab monotherapy at ten institutions in Japan, between February 2017 and February 2018. Data related to patient characteristics, efficacy of pembrolizumab therapy, and the type and severity of adverse events were recorded.

resultsOverall, 47 patients [40 men and 7 women; median age 79 (range 75-88) years] were included in our analysis. In patients who received first-line pembrolizumab monotherapy, overall response, disease control rates, median progression-free survival (PFS), and median overall survival (OS) were 53.1%, 74.4%, 7.0 months, and not reached, respectively. Common adverse events included anorexia, fatigue, skin rash, and hypothyroidism. Two treatment-related deaths were noted, due to pneumonitis and infection. First-line pembrolizumab monotherapy was associated with improved PFS in patients with non-progressive disease (PD). In patients with non-PD and good performance status (PS), pembrolizumab monotherapy improved OS.

conclusionsElderly patients with NSCLC expressing high PD-L1 tolerated front-line pembrolizumab monotherapy well. Their survival outcomes were equivalent to those of younger patients. In patients with non-PD, first-line pembrolizumab monotherapy may improve PFS; in conjunction with good PS, it additionally improves OS.

Indexed as

AgedAged, 80 and overAntibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalB7-H1 AntigenCarcinoma, Non-Small-Cell LungDisease-Free SurvivalFemaleHumansJapanLung NeoplasmsMaleProgression-Free SurvivalTreatment OutcomeAntibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalB7-H1 AntigenpembrolizumabAdvanced non-small cell lung cancerElderly patientsFirst-line pembrolizumab monotherapyPD-L1

Identifiers

PMID31853661
PMCPMC11804284
OpenAlexW2996119364

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.